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Abstract
Background: Platelet-derived growth factor (PDGF) D has been reported to be active in fibroblasts, and in areas of
myocardial infarction. In this longitudinal study we evaluated the association between PDGF-D polymorphism and
cardiovascular mortality, and attempted to discover whether specific genotype differences regarding risk could be
observed, and if gender differences could be seen.
Methods: Four hundred seventy-six elderly community participants were included in this study. All participants
underwent a clinical examination, echocardiography, and blood sampling including PDGF-D single nucleotide
polymorphism (SNP) analyses of the rs974819 A/A, G/A and G/G SNP. The follow-up time was 6.7 years.
Results: No specific genotype of rs974819 demonstrated increased cardiovascular mortality in the total population,
however, the male group with genotypes A/A and G/A demonstrated an increased risk that persisted in a
multivariate evaluation where adjustments were made for well-known cardiovascular risk factors (2.7 fold compared
with the G/G genotype). No corresponding finding was observed in the female group.
Conclusion: We report here for the first time that the genotypes G/A or A/A of the SNP rs974819 near PDGF-D
exhibited a 2.7 fold increased cardiovascular mortality risk in males. Corresponding increased risk could not be
observed in either the total population and thus not in the female group. However, the sample size is was small
and the results should be regarded as hypothesis-generating, and thus more research in the field is recommended.
Keywords: PDGF-D, rs974819, Genotypes, Gender, Prognosis, Cardiovascular risk
Abbreviations: BMI, Body mass index; EF, Ejection fraction; eGFR, Estimated glomerular filtration rate; MMP, Matrix
metalloproteinase; NT-proBNP, N-terminal fragment of pro B-type natriuretical peptide; NYHA, New York Heart
Association functional classification; PDGF, Platelet-derived growth factor; SD, Standard deviation; SNP, Single
nucleotide polymorphism
Background
The platelet-derived growth factor (PDGF) family pres-
ently consists of four members (PDGF-A, PDGF-B, and
the recently discovered PDGF-C and PDGF-D) [1–3].
The PDGF family perform a multitude of functions such
as vasodilation, regulation of erythropoiesis, and wound
repair [4], but are also major mitogens for fibroblasts
and smooth muscle cells, and are involved in the
atherosclerotic process in the body [5, 6]. PDGF-D has
also been reported active in conjunction with various
tumors, such as prostate cancer [7], and soft tissue
sarcomas [8].
After a myocardial infarction, increased levels of
PDGF-D in the infarcted tissue have been reported, a
fact that has been interpreted to indicate involvement of
PDGF-D in the repair process [9]. It has also been
shown that the PDGF-D expression is increased late
after a myocardial infarction, resulting in increased
production of interstitial fibroblasts [9]. PDGF-D has
also been shown to up-regulate the expression of matrix
metalloproteinase-1 (MMP-1), MMP-2 and MMP-9 in a
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rat model [10]. In a genome-wide association study of
risk loci for coronary heart disease in Europeans and in
South Asians, Peden et al. showed that rs974819 of
PDGF-D was one of the top 10 % of risk loci for coron-
ary heart disease [11]. This is in congruence with another
large-scale genome association study [12]. However, little
has been reported on rs974819 genotypes and risk of car-
diovascular death, and there has been no study of gender
differences regarding cardiovascular mortality.
The aim of this study was to evaluate the distribution
of the three genotypes G/G, G/A and A/A of rs974819
to see if any differences in cardiovascular mortality could
be registered in the three groups, and finally if gender
differences could be noted.
Methods
Patient population
The study population, were all part of a longitudinal
epidemiological study focusing on cardiovascular risk
factors, and were invited to participate in the present
sub-study conducted from 13th January 2003 to 18th
June 2005.
In 1999, all inhabitants aged 64–82 in a rural munici-
pality in south east Sweden were invited to take part in a
longitudinal study. In order to minimize bias in the se-
lection process of obtaining a representative population
of elderly persons, all those living in the municipality in
a specific age span were invited to participate in the
longitudinal project. Of 1162 subjects in the age 65–82,
876 (75 %) agreed to participate in the primary project.
When the present follow-up study was conducted four
to five years later 675 agreed to participate, and 476
agreed to deliver blood samples, and could present
Doppler-echocardiographical examinations with accept-
able quality. All participants underwent a clinical exam-
ination, ECG recording, and Doppler-echocardiography,
and blood samples were collected. The New York Heart
Association (NYHA) functional classification was evalu-
ated by the including physician based on the patient
information. All participants gave their written informed
consent, and the study was conducted in accordance
with the Declaration of Helsinki principles. The study
protocol was approved by the Regional Ethical Review
Board of Linköping, Sweden (Dnr 95044). The mortality
information was obtained after permission for this was
approved, from autopsy reports or from the National
Board of Health and Welfare in Sweden, which registers
all deaths. The causes of death are mainly based on
death certificates with about 10 % based on autopsies,
with potentially limited reliability. A recent study
suggests a 55 % accuracy of death certificates in cardio-
vascular disease in a Swedish community [13].
The main project has been presented in several previ-
ous publications [14–25].
Co-morbidity
Diabetes mellitus was defined as a previous diagnosis with
on-going treatment, or a fasting blood glucose ≥ 7 mmol/
L measured at one single occasion. Hypertension was
defined as a blood pressure of more than 140/90 mm Hg
measured in the right arm with the patient in the supine
position after at least 30 min rest. Patients were defined as
hypertensive if they had previously been diagnosed with
hypertension and were receiving antihypertensive medica-
tion. Ischemic heart disease was defined as a history of
angina pectoris/myocardial infarction or ECG-verified
myocardial infarction. Heart failure was defined as a previ-
ous diagnosis with on-going treatment, or symptoms/signs
of heart failure and objective demonstration of reduced
cardiac function in terms of impaired cardiac function on
echocardiography, or increased plasma concentration of
pro B-type natriuretical peptide (NT-proBNP) 1–76.
Echocardiography
Echocardiography examinations were performed using
an Accuson XP-128c with the patients in a supine left
position. Values for systolic function expressed as left
ventricular ejection fraction (EF), were categorized into
four classes with interclass limits of 30, 40 and 50 %.
Normal systolic function was defined as EF ≥ 50 %.
Biochemical analyses
All blood samples were obtained while the patients were at
rest in a supine position, and all samples were collected in
pre-chilled plastic Vacutainer tubes (Terumo EDTA K-3).
Plasma was prepared by centrifugation at 3000 g for
10 min at 4 °C. All samples were stored at −70 °C until ana-
lysis. None of the samples were thawed more than twice.
NT-proBNP was measured in the Elecsys 2010
platform (Roche Diagnostics, Mannheim, Germany). The
total CV was 4.8 % at 26 pmol/L and 2.1 % at 503 pmol/
L (n = 70) at our laboratory.
Genotype determination
Genomic DNA was isolated from peripheral blood using
the QIAmp DNA Mini Kit (QIAGEN, Hilden,
Germany), following the manufacturer’s instructions.
A LightSNiP genotyping assay (TIB Molbiol GmbH,
Berlin, Germany) was used for analysis of PDGF-D
(rs974819) genotypes. DNA was mixed with Reagent
Mix, LightCycler® FastStart DNA Master HybProbe
(Roche Diagnostics) and amplified using the LightCycler®
480 Real-Time PCR System (Roche Diagnostics).
Statistical methods
Descriptive data are presented as percentages or mean
and standard deviation (SD). Comparative analyses were
performed using the Student unpaired two-sided T-test,
whereas the chi-square test was used for discrete
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variables. Both univariate and multivariate Cox propor-
tional hazard regression analyses were used to analyse
and illustrate the risk of mortality during the follow-up
period, where both all-cause mortality and cardiovascu-
lar mortality were analysed. Kaplan-Meier graphs were
used to illustrate cardiovascular mortality as a function
of follow-up time. Censored patients were patients who
were still alive at the end of the study period or who had
died of other causes than cardiovascular disease. Com-
pleted patients comprised those who had died due to
cardiovascular disease. In the multivariate multivariable
regression model adjustment were made for the follow-
ing co-variates; age, diabetes, hypertension, ischemic
heart disease, body mass index (BMI), Hb < 120 g/L,
estimated glomerular filtration rate (eGFR) < 60 mL/min,
ACE- inhibitors/Angiotensin receptor blockers, beta
blockers, EF < 40 %, and s-cholesterol.
A P-value < 0.05 was considered statistically significant.
All data were analysed using standard software packages
(Statistica v. 12.0, Statsoft Inc, Tulsa, OK, USA).
Results
The basal characteristics of the 476 participants divided
into the two genders are presented in Table 1. The female
group had a higher BMI (27.6 vs. 26.7; P = 0.02), and also a
higher proportion of anaemia, here defined as Hb < 120 g/L
(35 vs. 16; P = 0.003), and a higher mean HDL (1.6 mmol/L
vs. 1.3 mmol/L; P < 0.0001). The male group exhibited a
significantly higher ratio of impaired systolic cardiac
function, here defined as EF < 40 % (27 vs. 9; P = 0.003)
(Table 1). In the total study population, 75 % had diagnosed
hypertension, 26 % were on treatment with ACE-
inhibitors/Angiotensin receptor blockers, and 35 % were on
treatment with beta-blockers. The mean follow-up time
was 6.7 years. During the follow-up period there was an all-
cause mortality of 22.3 % (106 out of 476), and of those
13.0 % (62 out of 476) suffered a cardiovascular mortality.
Mortality and genotypes PDGF-D rs974819
The genotype distribution and the distribution of all-
cause and cardiovascular mortality within the different
genotypes in the total study population and in the two
genders are presented in Tables 2 and 3. The frequency
of the A/A genotype was 8.8 % in the total population,
similar to a European population in the HapMap CEU
reporting of 7.3 %.
Intriguingly, the A/A frequency was more than twice
as high among females compared to males (29/234;
12.4 % vs. 13/242; 5.4 %) (Tables 2 and 3).
The cardiovascular mortality of the three genotypes in
the total study population during a follow-up period of
80 months was illustrated in a Kaplan-Meier graph (Fig. 1).
A power calculation indicated a sample size of males
to 290 participants (alpha:0.05, beta: 0.2, power: 0.8),
where 242 participants were recruited. For the female
group, the required sample size was 790 participants,
and where we reached 234 participants, thus a too small
to reach a possible significance.
The main finding is that the G/A and the A/A homo-
zygotes amalgamated into one group among the males
exhibit a higher incidence of both all-cause (P = 0.039)
and cardiovascular mortality (P = 0.008) compared to the
Table 1 Basal characteristics of the total study population and divided into genders
Variables Total population Females Males p-value
N 476 234 242
Age, mean (SD) 77 (3.4) 77 (3.7) 77 (3.2) 0.81
BMI, mean (SD) 27.2 (4.3) 27.6 (5.1) 26.7 (3.3) T =2.40; P = 0.02
IHD, n (%) 105 (22.1) 42 (17.9) 63 (26.0) X2 = 4.52;P = 0.03
Hypertension, n (%) 359 (75.4) 185 (79.1) 174 (71.9) 0.07
Diabetes, n (%) 154 (32.4) 68 (29.2) 86 (35.5) 0.13
ACEI/ARB, n (%) 125 (26.3) 61 (26.1) 64 (26.4) 0.73
Beta blockers, n (%) 168 (35.3) 78 (33.3) 90 (37.2) 0.38
Hb < 120 g/L, n (%) 51 (10.7) 35 (15.0) 16 (6.6) X2 = 8.66; P = 0.003
HDL, mmol/L mean, (SD) 1.5 (0.4) 1.6 (0.4) 1.3 (0.3) T =7.82;
P < 0.0001
CRP, mg/L, mean (SD) 11.0 (5.1) 11.0 (5.3) 10.8 (5.0) 0.68
EF < 40 %, n (%) 36 (7.6) 9 (3.8) 27 (11.2) X2 = 9.10;
P = 0.003
NT-proBNP ng/L, mean, (SD) 188 (319) 174 (200) 200 (395) 0.37
Notes: ACEI/ARB angiotensin converting enzyme inhibitor/Angiotensin receptor blocker, BMI body mass index, CRP C-reactive protein, EF ejection fraction, eGRF es-
timated glomerular filtration rate, HDL high density lipoproteins, IHD ischemic heart disease, NT-proBNP N-terminal fragment of proBNP
Note: P-value is based on comparison between females and males
Alehagen et al. BMC Medical Genetics  (2016) 17:62 Page 3 of 8
G/G genotype (Tables 2 and 3). This has been illustrated
in a Kaplan-Meier analysis showing that in the male
group, significantly more patients suffered cardiovascular
mortality among the G/A heterozygotes or the A/A ho-
mozygotes, compared to the G/G homozygotes (Fig. 2).
To evaluate increased cardiovascular mortality risk of
the G/A or A/A genotypes, a univariate Cox propor-
tional hazard regression analysis was performed.
In the total study population, the G/A or A/A genotypes
did not fulfil significant prognostic information (HR: 1.39;
P = 0.20 unadjusted; HR: 1.35; P = 0.24, when adjusted for
gender and age). However, in the male group a significant
increase in cardiovascular mortality risk of the G/A or A/A
variant could be demonstrated in the univariate Cox pro-
portional hazard regression (HR: 2.25; CI 95 % 1.23–4.10;
P = 0.008). In a multivariate model including clinical
variables known to influence cardiovascular risk, the G/A
or A/A genotypes still exhibited significant and independ-
ent prognostic information, with a 2.7 fold increased
cardiovascular mortality risk for the male participants with
those genotypes (Table 4).
In the female group the G/A or A/A genotypes did
not exhibit significant prognostic information regarding
cardiovascular mortality in the univariate Cox propor-
tional hazard regression analysis (HR: 0.48; P = 0.16). A
Kaplan-Meier graph illustrates the cardiovascular mor-
tality as a function of follow-up time of the G/A or A/A
genotypes in comparison to the G/G genotype of the fe-
male group could be seen in Fig. 3, where no difference
between the three genotypes could be demonstrated.
Discussion
Recently a discussion on how to optimally handle
patients with increased risk of cardiac events has been
launched, partly due to restricted health resources. The
inclusion of genetic markers into clinical routines has
also been discussed. In this study, PDGF-D has been
evaluated, partly because data in the literature indicate
that there is an association between the SNP rs974819
near PGDF-D, and coronary artery disease [12]. Another
reason is that PDGF-D is reported to be active in tissue
with active fibroblasts and smooth muscle cells, espe-
cially in cardiac tissue [6].
In the present study the G/G, G/A and A/A genotypes
of rs974819 have been evaluated in an elderly popula-
tion. The population evaluated consisted of subjects
from a rural Swedish municipality, and thus could be
regarded as representative of an elderly community
population. The differences between males and females
regarding basal characteristics were as expected (Table 1),
with more impaired cardiac function in the male group
and more patients with increased BMI in the female
group. The A/A genotype of rs974819 is by far the rarest
and was therefore difficult to evaluate from a risk per-
spective with the small number of subjects included.
Therefore, the A/A and the G/A genotypes have been
amalgamated into one group for comparison with the
G/G genotype in the multivariate risk evaluation
(Table 4), as well as in Figs. 2 and 3. Thus, in the evalua-
tions it seems that the male population with the G/A or
A/A genotypes exhibits higher mortality risk, especially
cardiovascular risk. However, a corresponding increased
risk in the total population, or in the female group
could, however, not be demonstrated. That males have a
higher cardiovascular risk, especially in ischemic events
is well-known [26, 27], even though the female group
catch up at higher age [28]. It is therefore interesting to
note the persisting difference in cardiovascular risk
Table 2 All-cause mortality in the study population distributed into the three analyzed genotypes of the PDGF-D gene
Note; n indicates the amount of all-cause mortality in relation to the total amount in the actual group
Note: in the X2-test, comparison between G/G versus G/A or A/A has been performed, as indicated in the brackets
Table 3 Cardiovascular mortality in the study population distributed into the three analyzed genotypes of the PDGF-D gene
Note; n indicates the amount of cardiovascular mortality in relation to the total amount in the actual group
Note: in the X2-test, comparison between G/G versus G/A or A/A has been performed, as indicated in the brackets
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between the three genotypes of rs974819 in this elderly
population. Even when adjustments have been made for
well-known clinical variables influencing cardiovascular
risk, the G/A or A/A genotypes were associated with a
2.7 fold increased cardiovascular risk in the male
population.
Zhou et al. presented an evaluation of 161 Chinese
patients with coronary heart disease compared to 112
controls, where different genotypes and alleles of
rs974819 were compared. They presented that rs 974819
was associated with coronary heart disease and that the
minor allele G was associated with a 45 % lower risk of
coronary heart disease compared to the A allele [29]. In
their study a greater proportion of the A allele could be
seen in the Chinese study population (0.68), as also
reported from South Asian studies (0.35), compared to
the European population (0.29), and also demonstrated
by Peden et al. [11]. In our population we could also
demonstrate a smaller proportion of the A/A genotype
of rs974819 compared to the other two genotypes.
However, comparisons were not straightforward due to
the large difference in allele frequency. Zhou presented
data indicating a higher incidence of coronary heart
disease in females with the A allele, but no difference
could be demonstrated in males regarding coronary
heart disease between the G and the A allele. In the
present study the male group with the G/A or A/A
genotypes demonstrated the highest cardiovascular
mortality risk, again probably as a result of ethnic differ-
ences, but possibly also as a result of different lifestyles
between the males and female populations that might
facilitate the disease progress. Comparing with the study
by Zhou et al., the present study applied a more definite
hard end-point; cardiovascular mortality compared to
coronary heart disease, as used by Zhou et.al. The differ-
ence in coronary heart disease/mortality between
females and males as reported in the present study com-
pared to the data presented by Zhao et al. from a
Chinese population could be partly explained by that
female patients seems to be more severely diseased and
have a worse prognosis compared to males [30]. In a
recent publication by Zimerman et al. where four differ-
ent trials on acute coronary syndrome was evaluated,
female gender was one independent variables for severe
adverse events [31]. In a substudy of the Valsartan in
Acute Myocardial Infarction Trial (VALIANT), the same
messages could be demonstrated, even if the size of male
group included with myocardial infarction was more
than double compared to the female size [32].
The present study has, however, applied an unusually
long follow-up time to evaluate the end-result of the
coronary heart disease process, and by applying a per-
spective over more than 6 years it might be possible to
identify possible differences in risk also in this relatively
small population. This might result in that more males
are identified compared to females.
The studied population was elderly, and those at high
risk had probably already died. However, in spite of this
it was possible to demonstrate differences in cardiovas-
cular mortality between genotypes.
Again, however, the obtained results of the present
study should be interpreted with caution, and should be
regarded as hypothesis-generating.
Fig. 1 Kaplan-Meier graph illustrating cardiovascular mortality
distributed into the genotypes G/G, G/A, and A/A of the SNP rs974819
in the total study population during 80 months of follow-up. Note:
Censored participants were those still living at the end of the study
period, or who had died of reasons other than cardiovascular disease.
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Fig. 2 Kaplan-Meier graph illustrating cardiovascular mortality
distributed into the G/A or A/A genotypes combined compared to
the G/G genotype of the SNP rs974819 in the male population
during 80 months of follow-up. Note: Censored participants were
those still living at the end of the study period, or who had died of
reasons other than cardiovascular disease. Completed participants
were those who had died due to cardiovascular disease
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Limitations
Several limitations could be identified. The first limitation
is the limited size of the study sample, which influenced
the statistical evaluation.
The high age of the included population could also be
regarded as a limitation, as it is not clear if the result
could be extrapolated into younger subjects. The geno-
types do not change with age, but there might be other
aging processes and comorbidities that, together with a
given genotype, might activate disease processes that
results in increased risk.
Finally, the included population consisted of a
homogenous population of Caucasians, so it is difficult to
draw conclusions for other population groups as the litera-
ture demonstrates ethnic differences in this respect [11].
In conclusion, the presented study should therefore be
regarded hypothesis- generating, and therefore more
research is needed.
Conclusion
The present study evaluated the three genotypes G/G, G/
A and A/A of the SNP rs974819 of PDGF-D in 476 elderly
community living individuals. From this a more than 2.7
fold increased cardiovascular mortality risk of the G/A or
A/A genotypes in the male group could be noted, but not
in the female group. This information could, in a situation
where health resources are restricted, be important in
order to identify patients at high cardiovascular risk, and
thereby motivate a tighter and more costly follow-up net
for those high risk patients.
However, as the sample size was small, the results
should be interpreted with caution, and this work should
be regarded more as a hypothesis-generating study.
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Fig. 3 Kaplan-Meier graph illustrating cardiovascular mortality
distributed into the G/A or A/A genotypes combined compared to
the G/G genotype of the SNP rs974819 in the female population
during 80 months of follow-up. Note: Censored participants were
those still living at the end of the study period, or who had died of
reasons other than cardiovascular disease. Completed participants
were those who had died due to cardiovascular disease
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